In an in-depth commentary for Pharmaceutical Market Europe, senior economist Jason Shafrin argues for real-world evidence (RWE) to become the “gold standard” of scientific evidence and heath technology assessments. (more…)
Precisioneffect Chief Creative Officer Deborah Lotterman pens a new commentary in the latest edition of MedAd News, “Making Sense of the Irrational.” (more…)
Senior Vice President Jeremy Schafer and Chief Creative Officer Deborah Lotterman submit a new commentary to MedAd News,“Enriching the Patient Journey: When Cost Creates Side Effects.” (more…)
In the latest edition of Managed Care, Precision for Value Payer Strategy Team members Ami Gopalan and Jeremy Schafer take a look at some of the cost-sharing strategies being employed by PBMs and ask the question, What latent effects might these programs have? (more…)
In the latest edition of Clinical Leader, Precision for Value’s Dominic Galante addresses how real-world evidence is being leveraged after the adoption of the 21st Century Cures Act, and provides some next steps for life science companies. (more…)
In a new article for Drug Discovery & Development, Precision Health Economics senior research economist Jason Shafrin addresses the use of real-world evidence, why we need it and how to effectively implement it. (more…)
Precision Health Economics Head of Medical, Dr. Ross Maclean, participates in a Q&A with patient advocate forum Conquer discussing the importance of personalized medicine. (more…)
In Managed Healthcare Executive, Precision Oncology’s Gerald Messerschmidt and Precision for Value’s Jeremy Schafer are tapped to provide their expert perspectives on the cost and value challenges facing the new class of CAR T-cell therapies. (more…)
Precision for Value is excited to be debuting a new publication– the Precision All Access Newsletter. All Access is an exclusive bi-monthly publication featuring key insights from our team of former payers intended specifically for market access leaders. (more…)
Pharmaceutical companies face many challenges: developing life-changing products that meet the needs of patients, physicians, and payers; adhering to regulatory standards; and managing health technology and payer scrutiny—all while trying to satisfy investors. (more…)